| Value | ₹2,530 Cr |
|---|
BSE filing, NSE: J&KBANK. Summary written from the filing by ALFA Finder's alert engine.
Jammu & Kashmir Bank Ltd: key numbers
- Share price
- ₹117.19
- Market cap
- ₹12,905 Cr
- Revenue (annual)
- ₹13,151 Cr
- Net profit (annual)
- ₹2,360 Cr
- P/E (TTM)
- 5.5×Sector 19.8×
- Promoter holding
- 59.40%+0.00% QoQ
- FII holding
- 11.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jammu & Kashmir Bank Ltd
All →Jammu & Kashmir Bank Legal & Regulatory
J&K Bank announces CBIC GST circular validates its FTP position, supporting quashing of two demand orders. Total GST liability at stake is ₹8,330.87 Crore.
- Value
- ₹8,331 Cr
Jammu & Kashmir Bank Earnings Call Transcript: Key Takeaways
Jammu & Kashmir Bank reported strong sequential profit growth driven by retail and MSME advances, while navigating CASA pressure.
- Call
- Guides 14% growth
Jammu & Kashmir Bank Investor Presentation: Key Takeaways
J&K Bank reported Q2FY27 net profit of ₹546 Cr (up 10.6% YoY) driven by strong credit growth and improved asset quality with record PCR of 91.76%.
Jammu & Kashmir Bank Results Update
J&K Bank reported Q2 FY27 net profit of ₹546 Cr, up 28.8% QoQ. Total business grew 19.4% to ₹3.10 lakh crore with decadal-best asset quality.
Jammu & Kashmir Bank Other Announcement
J&K Bank filed a routine Reg 32 statement confirming no deviation in utilisation of four prior preferential issues. All raised funds were fully deployed per original objects.
Jammu & Kashmir Bank Q2 FY27 Results: Net Profit ₹552.7 Cr, Up 11.7% YoY
Jammu & Kashmir Bank Ltd reported revenue from operations of ₹3,729 Cr (+13.2% YoY) and net profit of ₹552.7 Cr (+11.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹552.7 Cr · +11.7% YoY
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr